Overview

Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder

Status:
Completed

Trial end date:
2020-01-20

Target enrollment:

Participant gender:

Summary

Two-part study consisting of a double-blind, randomized, placebo-controlled, study at two target dose levels (Part 1) and an open-label, non-randomized study (Part 2) to determine the efficacy of ABX-1431 in treating adult patients with Tourette syndrome or Chronic Motor Tic Disorder as measured by the change from baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) compared with placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Abide Therapeutics

Collaborators:

BASi (Bioanalytical Systems, Inc.)
CogState Ltd.
FGK Clinical Research GmbH